Clinical AI Documentation Readiness Evaluation
An approved engagement gives the organization a Governance Decision Package that states what the available evidence supports, what remains uncertain or blocked, and whether the named clinical AI use case should Proceed, Modify, Pause, or Stop.
The engagement is bounded and time-limited. Scope and duration are set in the written Statement of Work and depend on site approvals, data readiness, and the named use case.
A bounded retrospective or approved read-only pilot for one named clinical AI use case. VitaSignal evaluates whether the local documentation pathway is sufficiently understood to support the next decision. The pilot produces a Governance Decision Package for human review. Engagement begins with a free 30-minute Readiness Evaluation Scoping Conversation: one named AI use case, the decision that has to be made, and what evidence is still missing. No data commitment.
Not ready to talk? Take the Documentation Readiness Index first. No meeting required.
Deliverable
What the organization receives
An approved engagement gives the organization a Governance Decision Package that states what the available evidence supports, what remains uncertain or blocked, and whether the named clinical AI use case should Proceed, Modify, Pause, or Stop.
The engagement is bounded and time-limited. Scope and duration are set in the written Statement of Work and depend on site approvals, data readiness, and the named use case.
1.Decision summary
The named use case, the decision on the table, and who owns it.
2.Evidence inventory and source boundaries
Which records, fields, and time windows were available, and which were not.
3.Supported, mixed, null or adverse, blocked, and not-run findings
Every result is reported in its own class. Negative and blocked findings are preserved.
4.Documentation-pathway map
Timing, availability, missingness, duplication, provenance, and mapping variation for that use case only.
5.Limitations and unresolved questions
What could not be evaluated, and what would be required to evaluate it.
6.Proceed, Modify, Pause, or Stop recommendation
A written recommendation for internal governance review. VitaSignal does not make the decision.
7.Owners, stopping conditions, and next-evidence requirements
Accountable owners, rollback or stopping conditions, and the evidence required before any next step.
8.Study-created burden record
Where applicable, the staff time spent on review, approvals, data preparation, interpretation, and governance participation.
Fields under consideration for future implementation
- Patient-disclosure decision, rationale, and owner.
- Consent decision, governing authority, rationale, and owner.
- Appropriate-reliance and human-factors risks.
- Incident and near-miss reporting route, threshold, owner, and preservation rule.
- Post-implementation monitoring plan covering drift, subgroup performance, workflow change, review interval, and stopping threshold.
These are fields for consideration or future implementation. They are not completed product capabilities and no validated outcome is claimed.
This is the structure of the deliverable, not a completed customer example and not proof of any outcome. No clinical, patient, workflow, staffing, fairness, ROI, savings, security, integration, or deployment benefit is established.
Scope and fees
Engagement structure
Every VitaSignal engagement is scoped and quoted in writing. The 30-minute Readiness Evaluation Scoping Conversation is free. Feasibility review and the Clinical AI Documentation Readiness Evaluation are separately scoped and contracted.
Stage 0
Readiness Evaluation Scoping Conversation
Free 30-minute qualification and scoping call. No data commitment and no custom written deliverable.
Stage 1
Feasibility review
Optional fixed-fee feasibility review, quoted for the specific opportunity.
Stage 2
Readiness evaluation
Site-specific, phase-gated evaluation on a retrospective extract or an approved read-only pathway, separately scoped and contracted. Scope and duration are set in the written Statement of Work and depend on approvals, data readiness, and the named use case. Silent-mode observation is not included; it is a possible later phase only under separate written authorization once all applicable technical, privacy, security, governance, contractual, and evidence gates are met.
Follow-on work
Separately scoped
Nothing is included by default. Evidence maintenance or any later evaluation is separately scoped, authorized, and contracted after the readout.
One platform, two working surfaces
VitaSignal is a single platform. Two workspaces carry the work: one holds the governance record, the other establishes what the local documentation pathway can support.
Governance Review Workspace
Keeps the decision in one place.
- Intended use and scope of the named use case
- Evidence and stated limitations, recorded together
- Risks, required controls, and accountable owners
- Decision states, evidence packs, and audit history
Data Pathway Readiness Workspace
Shows whether the local documentation pathway can support it.
- Mapping coverage and consistency
- Data quality and rejected records
- Source provenance and replay readiness
- Access audit evidence for review
What you receive
An evidence-backed, versioned Governance Decision Package: what was examined, what the evidence supports, which limitations apply, which controls are required, who owns each action, and a clear recommendation of Proceed, Modify, Pause, or Stop, with a record of what must happen next. VitaSignal recommends; the health system decides.
Discuss a Current Governance DecisionWhat happens after the evaluation?
The evaluation ends with a decision, not an obligation. These are the paths an organization can take. None of them is assumed, packaged, or priced in advance.
Close the evaluation
The question is answered and the record is complete. No further work is required.
Address the identified gaps
Resolve data, documentation, or control gaps internally before revisiting the decision.
Modify the use case
Narrow, redefine, or re-scope the intended use in response to what the evidence showed.
Maintain the evidence
Keep the baseline current through defined reassessment when conditions materially change.
Initiate material-change reevaluation
Reopen the review when a defined material change occurs.
Consider a separately scoped later evaluation
Any further evaluation is separately scoped, separately authorized, and separately contracted.
Evidence Maintenance
Evidence Maintenance is defined reassessment after a completed baseline evaluation, performed when evidence, data conditions, model or system versions, intended use, required controls, or unresolved findings materially change. It is an activity definition, not a published service, subscription, or commitment. No recurring engagement, recurring revenue, or established demand is claimed.
No follow-on work is included in the evaluation. Any later activity requires a separate written agreement.
Governance Decision Package
The final deliverable is four written elements suitable for internal governance review. VitaSignal does not make the decision.
Use-case boundary
One named AI use case, intended user, workflow, decision owner, and deadline, recorded in writing.
Documentation pathway review
Field availability, timing, provenance, missingness, duplication, and mapping variation for that use case only.
Evidence and limitations
What is already known, what remains unresolved, and what cannot be evaluated. Negative and blocked findings are preserved.
Governance decision record
Proceed, Modify, Pause, or Stop, with accountable owners and stopping rules. The organization owns the decision.
Founder-led
Dr. Alexis Collier runs the scoping conversation directly. A limited number are accepted each month.
No data commitment
The 30-minute scoping review is free. No data moves, and no fees apply, before scope is understood in writing.
Research-stage boundary
Retrospective or approved read-only evaluation only. No bedside alerts, no staffing decisions, no patient-care decisioning.
Final timing depends on site approvals, data readiness, and the written Statement of Work.
Request a Readiness Evaluation Scoping Conversation
Tell us the AI use case under consideration, who owns the decision, and what remains unresolved. No duration or data commitment is required before the scope is understood.
VitaSignal is research-stage governance decision-support technology. It is not FDA cleared or approved and is not available for clinical use. Intended use, product classification, and the applicable regulatory pathway remain under evaluation. Prospective validation and intended-use determination remain required.